Wenjing Xiao1, Jian-Ping Guo1, Chun Li1, Hua Ye1, Wei Wei2, Yaohong Zou3, Lie Dai4, Zhijun Li5, Miaojia Zhang6, Xiangpei Li7, Xiaoyan Cai8, Jianhong Zhao9, Youlian Wang10, Yi Tao11, Dongzhou Liu12, Yasong Li13, Min Wu14, Erwei Sun15, Lijun Wu16, Li Luo17, Rong Mu1, Zhanguo Li1. 1. Department of Rheumatology & Immunology, People's Hospital, Peking University, Beijing, PR China. 2. Department of Rheumatology & Immunology, Tianjin Medical University General Hospital, Tianjin, PR China. 3. Department of Rheumatology & Immunology, Wuxi People's Hospital, Wuxi, Jiangsu, PR China. 4. Department of Rheumatology & Immunology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, PR China. 5. Department of Rheumatology & Immunology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, PR China. 6. Department of Rheumatology & Immunology, The First Affiliated Hospital with Nanjing, Nanjing, Jiangsu, PR China. 7. Department of Rheumatology & Immunology, Anhui Provincial Hospital, Hefei, Anhui, PR China. 8. Department of Rheumatology & Immunology, Guangzhou First People's Hospital, Guangzhou, Guangdong, PR China. 9. Department of Rheumatology & Immunology, Jining No.1 People's Hospital, Jining, Shandong, PR China. 10. Department of Rheumatology & Immunology, Jiangxi Provincial People's Hospital, Xinyu, Jiangxi, PR China. 11. Department of Rheumatology & Immunology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, PR China. 12. Department of Rheumatology & Immunology, Shenzhen People's Hospital, Shenzhen, Guangzhou, PR China. 13. Department of Rheumatology & Immunology, Zhejiang Provincial People's Hospital, Huzhou, Zhejiang, PR China. 14. Department of Rheumatology & Immunology, The First People's Hospital of Changzhou, Changzhou, Jiangsu, PR China. 15. Department of Rheumatology & Immunology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, PR China. 16. Department of Rheumatology & Immunology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang Uygur Autonomous Region, PR China. 17. Department of Rheumatology & Immunology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, PR China.
Abstract
Iguratimod (IGU) is a novel disease-modifying anti-rheumatic drug (DMARD) in rheumatoid arthritis (RA). Like other DMARDs, IGU exhibited significant differences in effectiveness and safety. AIM: The aim of this study was to identify genetic predictorsof efficacyand toxicity of IGU in patients with RA. MATERIALS & METHODS: Seven SNPs from IGU-metabolizing genes were genotyped in 272 IGU-treated patients with RA. Results: ABCG2 rs2231142 A allele conferred a higher response to IGU, while NAT2 rs1495742 G carriersconferred a lower response to IGU. CYP2C19*2 rs4244285 A carriers had higher risk for IGU-induced toxicity compared to the GG carriers. CONCLUSION: Our study suggests that the polymorphisms of ABCG2 (rs2231142), NAT2 (rs1495741)and CYP2C19*2 (rs4244285) may help to predict thetherapeutic effectiveness and toxicity of IGU in patients with RA.
Iguratimod (IGU) is a novel disease-modifying anti-rheumatic drug (DMARD) in rheumatoid arthritis (RA). Like other DMARDs, IGU exhibited significant differences in effectiveness and safety. AIM: The aim of this study was to identify genetic predictorsof efficacyand toxicity of IGU in patients with RA. MATERIALS & METHODS: Seven SNPs from IGU-metabolizing genes were genotyped in 272 IGU-treated patients with RA. Results:ABCG2rs2231142 A allele conferred a higher response to IGU, while NAT2rs1495742 G carriersconferred a lower response to IGU. CYP2C19*2 rs4244285 A carriers had higher risk for IGU-induced toxicity compared to the GG carriers. CONCLUSION: Our study suggests that the polymorphisms of ABCG2 (rs2231142), NAT2 (rs1495741)and CYP2C19*2 (rs4244285) may help to predict thetherapeutic effectiveness and toxicity of IGU in patients with RA.